Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
Humans
Ribavirin
/ therapeutic use
Hepatitis C, Chronic
/ drug therapy
Antiviral Agents
/ therapeutic use
Follow-Up Studies
Treatment Outcome
Pyrophosphatases
/ genetics
Interferons
/ therapeutic use
Polymorphism, Single Nucleotide
Genotype
Hepacivirus
/ genetics
Liver Cirrhosis
/ drug therapy
Interleukins
/ genetics
Inosine Triphosphatase
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
27 Oct 2023
27 Oct 2023
Historique:
medline:
2
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
ppublish
Résumé
To investigate associations between inosine triphosphatase (ITPA) gene polymorphisms and long-term outcomes among chronic hepatitis C (CHC) patients in Northeast China treated with Peg-interferon (IFN)/ribavirin (RBV). CHC patients who received Peg-IFN-2a/RBV treatment during between 2011 and 2013 at 5 hepatitis centers in Northeast China were enrolled. ITPA single nucleotide polymorphisms rs1127354 and rs7270101 from all patients were detected and their associations with 5-year outcomes were analyzed. A total of 635 patients, including 421 infected with hepatitis C virus (HCV) genotype 1 and 214 infected with non-genotype 1 were included. No significant differences were observed in the distribution frequencies of ITPA rs1127354 variants and ITPase activity between patients with HCV genotype 1 and non-genotype 1. In patients who received more than 80% of the planned RBV dose, the 5-year virological response rate and the improvement in liver fibrosis were higher in those with ITPA rs1127354 non-CC with ITPase activity <25% compared with these outcomes in patients with ITPA rs1127354 CC with 100% ITPase activity. Multiple regression analysis revealed that HCV genotype non-1, low baseline HCV ribose nucleic acid (RNA) levels (≤4 × 105 IU/mL), interleukin-28B rs12979860 CC genotype, low baseline liver fibrosis (Fibroscan 0-2), and ITPA rs1127354 non-CC genotype were independent predictors for a high long-term virological response rate, whereas interleukin-28B rs12979860 CC genotype, ITPA rs1127354 non-CC genotype, and low baseline liver fibrosis were independent predictors for improvement of liver fibrosis. ITPA rs1127354 polymorphisms is predictors of long-term outcomes in CHC patients treated with Peg-IFN/RBV.
Identifiants
pubmed: 37904484
doi: 10.1097/MD.0000000000035508
pii: 00005792-202310270-00140
pmc: PMC10615403
doi:
Substances chimiques
Ribavirin
49717AWG6K
Antiviral Agents
0
Pyrophosphatases
EC 3.6.1.-
Interferons
9008-11-1
Interleukins
0
ITPA protein, human
EC 3.6.1.9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e35508Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
J Gastroenterol. 2017 Jun;52(6):746-753
pubmed: 27822709
Infect Disord Drug Targets. 2018;18(2):122-128
pubmed: 28595541
Hepatology. 2014 Jun;59(6):2131-9
pubmed: 24519039
Infect Disord Drug Targets. 2019;19(2):179-184
pubmed: 30207250
Infect Disord Drug Targets. 2017;17(2):95-100
pubmed: 28413993
Clin Chem. 2006 Feb;52(2):240-7
pubmed: 16384889
Hepatol Res. 2010 Nov;40(11):1063-71
pubmed: 20977565
J Hepatol. 2015 Jul;63(1):199-236
pubmed: 25911336
J Hepatol. 2011 Aug;55(2):245-64
pubmed: 21371579
Hepatol Int. 2016 Jan;10(1):158-68
pubmed: 26264253
Liver Int. 2017 Jun;37(6):802-808
pubmed: 28544696
Nature. 2010 Mar 18;464(7287):405-8
pubmed: 20173735
Hum Genet. 2002 Oct;111(4-5):360-7
pubmed: 12384777
PLoS One. 2016 Dec 20;11(12):e0167934
pubmed: 27997563
Mol Genet Metab. 2005 Aug;85(4):271-9
pubmed: 15946879
J Hepatol. 2016 Oct;65(4):727-733
pubmed: 27349488
Pharmacogenomics. 2007 Sep;8(9):1221-8
pubmed: 17924837
J Viral Hepat. 2017 Nov;24(11):976-981
pubmed: 28504854
Eur J Gastroenterol Hepatol. 2012 Aug;24(8):890-6
pubmed: 22584257
Gastroenterology. 2010 Oct;139(4):1181-9
pubmed: 20547162
J Korean Med Sci. 2013 Aug;28(8):1213-9
pubmed: 23960450
Hepat Mon. 2016 Oct 30;16(11):e41933
pubmed: 28070200
Medicine (Baltimore). 2017 Jul;96(29):e7554
pubmed: 28723780
N Engl J Med. 2002 Sep 26;347(13):975-82
pubmed: 12324553
J Hepatol. 2016 Oct;65(4):719-726
pubmed: 27084592